Fuller & Thaler Asset Management Inc. Purchases Shares of 862,744 CONMED Co. (NYSE:CNMD)

Fuller & Thaler Asset Management Inc. purchased a new stake in shares of CONMED Co. (NYSE:CNMD - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 862,744 shares of the company's stock, valued at approximately $59,046,000. Fuller & Thaler Asset Management Inc. owned approximately 2.79% of CONMED at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. increased its position in CONMED by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 3,574,420 shares of the company's stock worth $244,633,000 after buying an additional 44,777 shares in the last quarter. Capital Research Global Investors lifted its position in CONMED by 2.1% during the fourth quarter. Capital Research Global Investors now owns 1,577,172 shares of the company's stock valued at $107,942,000 after purchasing an additional 32,630 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in CONMED by 8.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 775,440 shares of the company's stock valued at $53,073,000 after purchasing an additional 57,149 shares during the last quarter. Principal Financial Group Inc. lifted its position in CONMED by 0.7% during the fourth quarter. Principal Financial Group Inc. now owns 625,058 shares of the company's stock valued at $42,780,000 after purchasing an additional 4,343 shares during the last quarter. Finally, Clearbridge Investments LLC lifted its position in CONMED by 9.4% during the fourth quarter. Clearbridge Investments LLC now owns 542,966 shares of the company's stock valued at $37,161,000 after purchasing an additional 46,582 shares during the last quarter.

Analyst Ratings Changes

Several research firms have recently issued reports on CNMD. Wells Fargo & Company lowered their target price on shares of CONMED from $74.00 to $70.00 and set an "equal weight" rating for the company in a report on Thursday, February 6th. Needham & Company LLC dropped their target price on CONMED from $97.00 to $91.00 and set a "buy" rating on the stock in a research report on Thursday, February 6th. JPMorgan Chase & Co. cut CONMED from an "overweight" rating to a "neutral" rating and lowered their target price for the stock from $85.00 to $70.00 in a report on Thursday, February 6th. Finally, Stifel Nicolaus cut CONMED from a "buy" rating to a "hold" rating and decreased their price objective for the company from $75.00 to $55.00 in a report on Monday. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $73.20.

CONMED Stock Up 1.2 %

Shares of NYSE:CNMD traded up $0.60 on Tuesday, reaching $51.44. The company had a trading volume of 86,125 shares, compared to its average volume of 448,742. The company has a quick ratio of 1.06, a current ratio of 2.30 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $1.59 billion, a P/E ratio of 12.13, a P/E/G ratio of 1.83 and a beta of 1.28. The stock has a 50-day moving average price of $56.75 and a 200 day moving average price of $65.09. CONMED Co. has a twelve month low of $46.00 and a twelve month high of $78.58.

CONMED (NYSE:CNMD - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.20 by $0.14. CONMED had a return on equity of 14.31% and a net margin of 10.13%. On average, equities analysts expect that CONMED Co. will post 4.35 EPS for the current year.

CONMED Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 4th. Shareholders of record on Friday, March 14th were given a $0.20 dividend. The ex-dividend date was Friday, March 14th. This represents a $0.80 annualized dividend and a yield of 1.56%. CONMED's payout ratio is 18.87%.

CONMED Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.